Endocrinologic syndromes part I

Endocrinologic syndromes
hypercalcemia hypercalcemia could be a fairly common metabolic
problem related to malignancies. 103 many pathologic
mechanisms are proposed, as well as osteolytic
bone metastases or humoral and cytokine factors like
parathyroid hormone–related protein (pthrp), transforming
growth factor- , il-1, tnf, prostaglandins, and lymphotoxin.
104, 105 bender and hansen 106 reviewed 200 consecutive
cases of bronchogenic lung cancer and located a twelve. 5% incidence
of hypercalcemia. hypercalcemia related to carcinoma
of the lung will occur with bone metastases other then often
occurs within the absence of osseous involvement. squamous
cell carcinoma is the foremost common histology associated this
paraneoplastic presentation, typically befored-stage disease.
107 hypercalcemia rarely occurs in little cell carcinoma
even supposing different paraneoplastic syndromes are common in
this malignancy. 108 benign conditions might be chargeable for
hypercalcemia in cancer patients. an example of this relationship
would be coexistence of primary hyperparathyroidism
with the malignancy. 109
calcium is controlled by the interaction of parathyroid
hormone (pth), one, 25-dihydroxyvitamin d, and calcitonin in
the bone, kidney, and gastrointestinal tract. pth stimulates
bone resorption, renal calcium reabsorption within the distal renal
tubules, and production of vitamin d by the kidney. patients
with cancer-related hypercalcemia will have increased pth activity
within their blood. a hundred and ten immunoreactive pth levels are usually
low or normal ; though, a pthrp may be detected within the
serum. 111 this protein product is homologous with pth at
the amino terminus, that is that the portion that binds to the
pth receptor. 112 the gene chargeable for pthrp expression
is located on the short arm of chromosome twelve. pthrp acts as a
hormone that stimulates bone resorption and renal phosphate
wasting, leading to hypercalcemia and hypophosphatemia. it
has been advised that lung cancer patients with hypercalcemia
and elevated pthrp levels might have the next likelihood of
bone metastases and a shorter survival. 113
clinical symptoms related to hypercalcemia may be
variable counting on the level of serum calcium and rapidity
with that the level was achieved. early manifestations can
embrace nausea and vomiting, fatigue, lethargy, anorexia, muscle
weakness, constipation, pruritus, polyuria, and polydipsia.
the symptoms might not be recognized as a result of they may be
connected to the existing malignancy, treatment toxicities (i. e.,
chemotherapy, narcotics), and different comorbid conditions.
if untreated, patients may become severely dehydrated, subsequently
developing renal insufficiency. glomerular filtration
is decreased, and a reversible defect within the kidney can
result in loss of urine-concentrating ability. 114 neurologic
manifestations will too be considerably worsened, resulting
in confusion, obtundation, psychosis, seizures, and coma.
more effects on the gastrointestinal tract will result in obstipation
and that ileus. electrocardiographic changes will occur
with a prolonged pr interval, shortened qt interval, and a
wide t wave. this may result in bradycardia and atrial or ventricular
arrhythmias. poor performance standing, advanced age,
and preexisting renal and hepatic dysfunction will increase the
effects of hypercalcemia